Antibody avidity measurements in recipients of Cervarix vaccine following a two-dose schedule or a three-dose schedule.
作者： Mathieu Boxus , Laurence Lockman , Michel Fochesato , Clarisse Lorin , Florence Thomas
DOI: 10.1016/J.VACCINE.2014.04.005
关键词:
摘要: The HPV-16/18 vaccine (Cervarix®) is a prophylactic for the prevention of cervical cancer and contains recombinant virus-like particles (VLPs) assembled from L1 major capsid proteins human papillomavirus (HPV) strains 16 18. Although correlate protection has yet to be identified, HPV-specific antibodies are thought prevent virus infection genital mucosa. Therefore, antigen-specific as assessed by ELISA or pseudovirion-based neutralisation assay frequently measured in clinical trials substantiate immune responses induced vaccine. Measuring antigen-antibody binding avidities, which reflects degree affinity maturation B-cells, another valuable method assess quality antibody responses. Here we describe avidities samples taken trial examining feasibility adopting two-dose (Months 0 6) schedule 9–14 year olds instead three-dose 0, 1 6). Antibody avidity (i.e. index [AI]) was determined ratio concentrations serum treated not with chaotropic agent NaSCN. Importantly, comparison between groups recipients, no differences AIs were observed at Months 7, 24 48. results suggest that Month 7 48, response terms similar recipients recipients. Hence these support adoption year-old girls.
core.ac.uk
sci-hub.se 参考文章(34)
Doris M Rivera Medina, Alejandra Valencia, Alet de Velasquez, Li-Min Huang, Roman Prymula, Jose García-Sicilia, Lars Rombo, Marie Pierre P David, Dominique Descamps, Karin Hardt, Gary Dubin, HPV-013 Study Group, Safety and Immunogenicity of the HPV-16/18 AS04-Adjuvanted Vaccine: A Randomized, Controlled Trial in Adolescent Girls Journal of Adolescent Health. ,vol. 46, pp. 414- 421 ,(2010) , 10.1016/J.JADOHEALTH.2010.02.006
Harald zur Hausen, Papillomaviruses in the causation of human cancers — a brief historical account Virology. ,vol. 384, pp. 260- 265 ,(2009) , 10.1016/J.VIROL.2008.11.046
Mark H. Einstein, Mira Baron, Myron J. Levin, Archana Chatterjee, Bradley Fox, Sofia Scholar, Jeffrey Rosen, Nahida Chakhtoura, Dorothée Meric, Francis J. Dessy, Sanjoy Kumar Datta, Dominique Descamps, Gary Dubin, Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years. Human Vaccines. ,vol. 7, pp. 1343- 1358 ,(2011) , 10.4161/HV.7.12.18281
Y. Schlesinger, D. M. Granoff, T. V. Murphy, M. T. Osterholm, J. E. McHugh, R. Anderson, J. Esbenshade, M. Blatter, K. S. Reisinger, H. Keyserling, K. Guito, C. K. Meschievitz, , Avidity and Bactericidal Activity of Antibody Elicited by Different Haemophilus influenzae Type b Conjugate Vaccines JAMA: The Journal of the American Medical Association. ,vol. 267, pp. 1489- 1494 ,(1992) , 10.1001/JAMA.1992.03480110065035
Joseph G. Dauner, Yuanji Pan, Allan Hildesheim, Clayton Harro, Ligia A. Pinto, Characterization of the HPV-specific memory B cell and systemic antibody responses in women receiving an unadjuvanted HPV16 L1 VLP vaccine. Vaccine. ,vol. 28, pp. 5407- 5413 ,(2010) , 10.1016/J.VACCINE.2010.06.018
Joseph G. Dauner, Yuanji Pan, Allan Hildesheim, Troy J. Kemp, Carolina Porras, Ligia A. Pinto, Development and application of a GuHCl-modified ELISA to measure the avidity of anti-HPV L1 VLP antibodies in vaccinated individuals Molecular and Cellular Probes. ,vol. 26, pp. 73- 80 ,(2012) , 10.1016/J.MCP.2012.01.002
Barbara Romanowski, Tino F. Schwarz, Linda M. Ferguson, Klaus Peters, Marc Dionne, Karin Schulze, Brian Ramjattan, Peter Hillemanns, Grégory Catteau, Kurt Dobbelaere, Anne Schuind, Dominique Descamps, Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: Results from a randomized study Human Vaccines. ,vol. 7, pp. 1374- 1386 ,(2011) , 10.4161/HV.7.12.18322
F.M. Russell, A. Balloch, P.V. Licciardi, J.R. Carapetis, L. Tikoduadua, L. Waqatakirewa, Y.B. Cheung, E.K. Mulholland, M.L.K. Tang, Serotype-specific avidity is achieved following a single dose of the 7-valent pneumococcal conjugate vaccine, and is enhanced by 23-valent pneumococcal polysaccharide booster at 12 months. Vaccine. ,vol. 29, pp. 4499- 4506 ,(2011) , 10.1016/J.VACCINE.2011.04.038
Louise J McHeyzer-Williams, Nadege Pelletier, Linda Mark, Nicolas Fazilleau, Michael G McHeyzer-Williams, Follicular helper T cells as cognate regulators of B cell immunity Current Opinion in Immunology. ,vol. 21, pp. 266- 273 ,(2009) , 10.1016/J.COI.2009.05.010
Carola G. Vinuesa, Stuart G. Tangye, Bernhard Moser, Charles R. Mackay, Follicular B helper T cells in antibody responses and autoimmunity. Nature Reviews Immunology. ,vol. 5, pp. 853- 865 ,(2005) , 10.1038/NRI1714